Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30-positive Lymphoma”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06550336
What this trial is testing

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

Who this might be right for
Peripheral T Cell Lymphoma
The First Hospital of Jilin University 35
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Early research (Phase 1)Study completedNCT02822586
What this trial is testing

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Who this might be right for
Mycosis FungoidesSézary Syndrome
Virginia Commonwealth University 5
Not applicableStudy completedNCT05506774
What this trial is testing

People With CD30 Positive Lymphoma in China

Who this might be right for
Lymphoma
Takeda 1,006
Early research (Phase 1)WithdrawnNCT02780011
What this trial is testing

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

Who this might be right for
CD30-positive LymphomaCD30-positive Solid Tumor
Eric Bernicker, MD
Early research (Phase 1)Study completedNCT00430846
What this trial is testing

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Who this might be right for
Lymphoma, Non-HodgkinDisease, HodgkinLymphoma, Large-Cell, Anaplastic
Seagen Inc. 45
Not applicableLooking for participantsNCT05481437
What this trial is testing

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Takeda 8
Testing effectiveness (Phase 2)WithdrawnNCT02729961
What this trial is testing

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveCD30-Positive Neoplastic Cells PresentSystemic Anaplastic Large Cell Lymphoma
University of Washington
Early research (Phase 1)Study completedNCT03302728
What this trial is testing

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Who this might be right for
Lymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralHodgkin Lymphoma
Peter MacCallum Cancer Centre, Australia 6
Early research (Phase 1)Study completedNCT01026233
What this trial is testing

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Seagen Inc. 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT01352520
What this trial is testing

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Who this might be right for
CD-30 Positive Anaplastic Large T-cell Cutaneous LymphomaLymphoma, Primary Cutaneous Anaplastic Large CellLymphomatoid Papulosis+5 more
M.D. Anderson Cancer Center 79
Testing effectiveness (Phase 2)Ended earlyNCT05883449
What this trial is testing

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
Affimed GmbH 25
Early research (Phase 1)WithdrawnNCT04952584
What this trial is testing

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine
Testing effectiveness (Phase 2)UnknownNCT05316246
What this trial is testing

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Early research (Phase 1)Study completedNCT00634452
What this trial is testing

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Who this might be right for
Hodgkin's Lymphomas
Bristol-Myers Squibb 22
Testing effectiveness (Phase 2)Study completedNCT04101331
What this trial is testing

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Who this might be right for
Peripheral T Cell LymphomaTransformed Mycosis Fungoides
Affimed GmbH 108
Not applicableLooking for participantsNCT06850285
What this trial is testing

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Who this might be right for
Lymphoma, B-Cell
Shanxi Bethune Hospital 15
Testing effectiveness (Phase 2)Ended earlyNCT02169505
What this trial is testing

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 2
Testing effectiveness (Phase 2)WithdrawnNCT04334174
What this trial is testing

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

Who this might be right for
T Cell Lymphoma
University of Kansas Medical Center
Load More Results